Prostate cancer biomarker: from bench to clinic

Experts Meeting on Cancer Medicine, Radiology & Treatment

April 11-12, 2022 | Webinar

Jianqing Lin

Washington University School of Medicine and Health Sciences, USA

Scientific Tracks Abstracts: J Cancer Sci Ther

Abstract :

There are several prognostic models for predicting overall survival (OS) of patients with metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor cell (CTCs) enumeration at baseline and its conversion post systemic treatment are the most accurate and independent predictor of OS in mCRPC. This talk will cover the biomarker aspect of mCRPC patients CTCs and current research related to its predictive value of CTCs AR-V7 analysis in selecting novel androgen receptor signaling inhibitors, prognostic value of CTC cluster; CTCs heterogeneity and future adaptive therapeutic selection based on single cell CTC genomic and transcriptomes analysis. In the predictive biomarker front, clinical utility of the analysis of AR-V7, DNA damage repair pathway gene, PSMA, tumor mutation burden and MSI status in prostate cancer will be discussed.

Biography :

Jianqing Lin earned his medical degree at Zhejiang Medical University in China and clinical fellowship training in Medical Oncology at Johns Hopkins University School of Medicine, USA. He is the co-program leader in genitourinary oncology of the GW Cancer Center and Associate Professor of Medicine at The George Washington University School of Medicine & Health Sciences. He has over 50 publications in national and international journals and has been serving editorial board member of several journals.